Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of MK-3402 in Renal Impairment
NCT04678505Phase 1Terminated
- Sponsor
- Merck & Co.
- Start
- Feb 2021
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of MK-3402 in bacterial infection and Antimicrobial resistant infections (AMR) (5 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Curve From Dosing to Infinity at 48 hours, Plasma Concentration at the End of Infusion at 48 hours and 4 more. Started Feb 2021; status: terminated.
02
Drugs
MK-3402
03
Conditions
bacterial infectionAntimicrobial resistant infections (AMR)
Beyond the preview
Go deeper on NCT04678505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04678505.